DGNOF: AI 评分 36/100 — AI 分析 (4月 2026)

DIAGNOS Inc. specializes in software-based healthcare services, primarily Computer Assisted Retina Analysis (CARA), a tool for detecting diabetic retinopathy. The company operates in multiple countries, offering both diagnostic services and consulting in data analysis and artificial intelligence.

Key Facts: AI Score: 36/100 Sector: Healthcare

公司概况

概要：

DIAGNOS Inc. provides software-based healthcare solutions, focusing on early detection of diabetic retinopathy through its CARA platform. Operating across several countries, the company leverages AI and data analysis to enhance diagnostic capabilities for eye care professionals, positioning itself in the evolving landscape of healthcare information services.

DGNOF是做什么的？

Founded in 1998 and headquartered in Brossard, Canada, DIAGNOS Inc. has established itself as a provider of software-based services within the healthcare sector. The company's core offering is the Computer Assisted Retina Analysis (CARA) platform, a web-based tool designed to aid healthcare professionals in the early detection of diabetic retinopathy. This technology allows eye care specialists to visualize retinal landmarks and identify pathological changes indicative of the disease. DIAGNOS operates across Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica, reflecting a global reach in its service delivery. Beyond its diagnostic software, DIAGNOS also provides consulting services in data analysis and artificial intelligence, leveraging its expertise to offer broader solutions within the healthcare industry. The company's focus on innovative technology and international expansion underscores its commitment to improving healthcare outcomes through advanced diagnostic tools and services.

DGNOF的投资论点是什么？

DIAGNOS Inc. presents a speculative investment opportunity within the healthcare information services sector. The company's CARA platform addresses a critical need for early detection of diabetic retinopathy, a growing concern globally. However, with a negative P/E ratio of -7.48 and a significantly negative profit margin of -6907.3%, the company's financial performance raises concerns about its profitability and sustainability. The potential for growth lies in expanding the adoption of the CARA platform and leveraging its AI and data analysis capabilities. Investors should closely monitor the company's ability to improve its financial metrics and secure additional contracts in its target markets. The low Beta of -0.17 suggests the stock is less volatile than the market, but this may also reflect limited trading activity and investor interest.

DGNOF在哪个行业运营？

DIAGNOS Inc. operates within the healthcare information services sector, which is experiencing growth driven by technological advancements and increasing demand for efficient diagnostic tools. The market for AI-powered diagnostic solutions is expanding, with companies like DIAGNOS leveraging these technologies to improve healthcare outcomes. The competitive landscape includes established players in medical imaging and diagnostics, as well as emerging companies focused on AI-driven healthcare solutions. DIAGNOS's focus on diabetic retinopathy detection positions it within a specific niche of the broader healthcare IT market.

Medical - Healthcare Information Services

Healthcare

DGNOF有哪些增长机遇？

Expansion of CARA Platform Adoption: DIAGNOS has the opportunity to increase the adoption of its CARA platform among healthcare providers globally. The rising prevalence of diabetes and the need for early detection of diabetic retinopathy create a significant market. By targeting regions with limited access to specialized eye care, DIAGNOS can expand its market share and generate recurring revenue through software subscriptions and service fees. Market research indicates the global diabetic retinopathy market is projected to reach $4.6 billion by 2027, offering substantial growth potential.
Strategic Partnerships with Healthcare Providers: Forming strategic partnerships with hospitals, clinics, and eye care centers can accelerate the adoption of DIAGNOS's CARA platform. These partnerships can provide access to a broader patient base and facilitate the integration of CARA into existing clinical workflows. By collaborating with key opinion leaders and participating in industry conferences, DIAGNOS can enhance its visibility and credibility within the healthcare community. The timeline for establishing these partnerships is estimated at 1-2 years, with potential revenue impact within 2-3 years.
Development of New AI-Powered Diagnostic Tools: DIAGNOS can leverage its expertise in AI and data analysis to develop new diagnostic tools for other medical conditions. By expanding its product portfolio, the company can diversify its revenue streams and reduce its reliance on a single product. Potential areas for expansion include cardiovascular disease, neurological disorders, and cancer screening. The development of new AI-powered diagnostic tools requires significant investment in research and development, with a timeline of 2-3 years for product launch.
Geographic Expansion into Emerging Markets: DIAGNOS can expand its geographic presence into emerging markets with high rates of diabetes and limited access to specialized eye care. These markets offer significant growth potential due to the unmet need for affordable and accessible diagnostic solutions. By adapting its CARA platform to local languages and regulatory requirements, DIAGNOS can penetrate these markets and establish a strong foothold. The timeline for geographic expansion is estimated at 1-2 years, with potential revenue impact within 2-3 years.
Leveraging Telemedicine for Remote Diagnostics: Integrating the CARA platform with telemedicine services can enable remote diagnostics and expand access to eye care in underserved areas. By partnering with telemedicine providers, DIAGNOS can offer its diagnostic services to patients who may not have access to traditional healthcare facilities. This approach can also reduce the cost of healthcare delivery and improve patient outcomes. The integration of CARA with telemedicine platforms requires collaboration with technology providers and regulatory approvals, with a timeline of 1-2 years for implementation.

Market capitalization of $0.02 billion indicates a micro-cap company with potential for high growth but also significant risk.
Negative P/E ratio of -7.48 reflects current unprofitability, requiring careful monitoring of future earnings potential.
Gross margin of -2090.9% signals substantial challenges in cost management and pricing strategies.
The company's focus on Computer Assisted Retina Analysis (CARA) positions it in a niche market with potential for expansion.
Operations across multiple countries, including Canada, the United States, and several Latin American nations, provide geographic diversification.

DGNOF提供哪些产品和服务？

Provides Computer Assisted Retina Analysis (CARA) software.
CARA assists in the early detection of diabetic retinopathy.
Offers a web-based platform for healthcare professionals.
Visualizes retinal landmarks and pathological changes.
Provides consulting services in data analysis.
Offers expertise in artificial intelligence for healthcare applications.

DGNOF如何赚钱？

Software-as-a-Service (SaaS) model for the CARA platform.
Revenue from subscriptions and service fees.
Consulting services in data analysis and AI.
Partnerships with healthcare providers and telemedicine companies.

Eye care specialists
Hospitals and clinics
Healthcare providers
Telemedicine companies

Proprietary Computer Assisted Retina Analysis (CARA) software.
Expertise in AI and data analysis for healthcare.
Established presence in multiple countries.
Partnerships with healthcare providers.

什么因素可能推动DGNOF股价上涨？

Upcoming: Potential new partnerships with healthcare providers to expand CARA platform adoption.
Ongoing: Increasing prevalence of diabetes driving demand for diabetic retinopathy detection solutions.
Ongoing: Development of new AI-powered diagnostic tools to diversify revenue streams.

DGNOF的主要风险是什么？

Potential: Competition from larger healthcare companies with more resources.
Potential: Regulatory changes in healthcare affecting the adoption of AI-powered diagnostic tools.
Ongoing: Negative P/E ratio and profit margin indicating financial instability.
Potential: Limited liquidity and wider bid-ask spreads on the OTC market.

DGNOF的核心优势是什么？

Proprietary CARA platform for diabetic retinopathy detection.
Expertise in AI and data analysis.
Established presence in multiple countries.
Focus on a specific niche within healthcare.

DGNOF的劣势是什么？

Negative P/E ratio and profit margin.
Limited financial resources.
Reliance on a single product (CARA).
Small market capitalization.

DGNOF有哪些机遇？

Expansion of CARA platform adoption.
Strategic partnerships with healthcare providers.
Development of new AI-powered diagnostic tools.
Geographic expansion into emerging markets.

DGNOF面临哪些威胁？

Competition from larger healthcare companies.
Regulatory changes in healthcare.
Technological advancements that could render CARA obsolete.
Economic downturn affecting healthcare spending.

DGNOF的竞争对手是谁？

A Health Innovation Group Inc — Focuses on digital health solutions. — (AHGIF)
Bio-Matrix Scientific Group Inc — Offers regenerative medicine products. — (BBIXF)
Biome Technologies PLC — Develops bio-based and biodegradable plastics. — (BMKDF)
Curaleaf Holdings Inc — Operates in the cannabis industry. — (CLIFF)
Clarify Medical Inc — Focuses on dermatology solutions. — (CLYYF)

Key Metrics

MoonshotScore: 36/100

Company Profile

CEO: Andre Larente
Headquarters: Brossard, CA
Founded: 2003

AI Insight

AI analysis pending for DGNOF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does DIAGNOS Inc. do?

DIAGNOS Inc. specializes in providing software-based healthcare services, primarily focusing on the early detection of diabetic retinopathy through its Computer Assisted Retina Analysis (CARA) platform. This web-based tool assists healthcare professionals in visualizing retinal landmarks and identifying pathological changes indicative of the disease. In addition to its diagnostic software, DIAGNOS offers consulting services in data analysis and artificial intelligence, catering to the broader needs of the healthcare industry. The company operates across multiple countries, including Canada, the United States, and several Latin American nations, reflecting its global reach and commitment to improving healthcare outcomes through advanced technology.

What do analysts say about DGNOF stock?

As of March 16, 2026, there is limited analyst coverage specifically for DGNOF stock due to its OTC listing and small market capitalization. Key valuation metrics, such as the negative P/E ratio and profit margin, suggest that the company is currently unprofitable. Growth considerations revolve around the successful adoption of the CARA platform and the development of new AI-powered diagnostic tools. Investors should conduct their own thorough research and consider the risks associated with investing in micro-cap companies on the OTC market. There is no consensus rating available.

What are the main risks for DGNOF?

The main risks for DIAGNOS Inc. include its negative financial performance, as indicated by its negative P/E ratio and profit margin, which raises concerns about its financial sustainability. Competition from larger healthcare companies with more resources poses a threat to its market share. Regulatory changes in healthcare could affect the adoption of its AI-powered diagnostic tools. Additionally, the company's reliance on a single product (CARA) makes it vulnerable to technological advancements that could render its platform obsolete. As an OTC-listed stock, DGNOF also faces risks related to limited liquidity and transparency.